目的:探讨Ubc9在人肺癌组织中的表达及临床意义。方法:应用免疫组织化学法和实时荧光定量PCR(real time quantitative PCR,RT-qPCR)法检测143例肺癌组织及同源非癌变组织中Ubc9的表达情况,并对临床病理资料进行分析。结果:与癌旁组织相...目的:探讨Ubc9在人肺癌组织中的表达及临床意义。方法:应用免疫组织化学法和实时荧光定量PCR(real time quantitative PCR,RT-qPCR)法检测143例肺癌组织及同源非癌变组织中Ubc9的表达情况,并对临床病理资料进行分析。结果:与癌旁组织相比,Ubc9在肺癌组织中呈高表达(P<0.05),Ubc9的表达与年龄、淋巴结转移、TNM分期及预后密切相关,有统计学意义(P<0.05);而与性别、病理学类型、组织分化程度无关。结论:小细胞肺癌、肺鳞癌和肺腺癌中均有Ubc9阳性表达,均高于正常的肺组织,并且与肺癌淋巴结转移程度相关,提示Ubc9可能与肺癌细胞的转移特性有关。展开更多
Ubiquitin-conjugating enzyme 9(Ubc9),the sole conjugating enzyme for sumoylation,regulates protein function and plays an important role in tumorigenesis.Whether Ubc9 is involved in the chemoresistance of breast cancer...Ubiquitin-conjugating enzyme 9(Ubc9),the sole conjugating enzyme for sumoylation,regulates protein function and plays an important role in tumorigenesis.Whether Ubc9 is involved in the chemoresistance of breast cancer remains unknown.In this study,we aimed to evaluate the contribution of Ubc9 in the chemoresistance of breast cancer.Immunohistochemistry(IHC) was used to examine the expression level of Ubc9.Chi-square test,Wilcoxon test,and one-way ANOVA were applied to analyze the relationship between Ubc9 expression,clinicopathologic features,and clinical response to neoadjuvant chemotherapy.The significance of variables for survival was analyzed by the Cox proportional hazards model in a multivariate analysis.Kaplan-Meier survival curves were plotted and log-rank test was performed.The proportion of Ubc9-positive cells was higher in invasive ductal carcinoma than in normal breast tissues [(48.48 ± 17.94)% vs.(5.82 ± 2.80)%,P < 0.001].High Ubc9 expression was associated with poor differentiation(χ2 = 6.538,P = 0.038),larger tumor size(χ2 = 4.701,P = 0.030),advanced clinical stage(χ2 = 4.651,P = 0.031),lymph node metastasis(χ2 = 9.913,P = 0.010),basal-like phenotype(χ2 = 8.660,P = 0.034),and poor clinical response to neoadjuvant chemotherapy(χ2 = 11.09,P = 0.001).The expected 6-year cumulative disease-free survival rate was 87.32% in patients with low Ubc9 expression compared to 68.78% in those with high Ubc9 expression(χ2 = 4.289,P = 0.038).These data indicate that high Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis.展开更多
文摘目的:探讨Ubc9在人肺癌组织中的表达及临床意义。方法:应用免疫组织化学法和实时荧光定量PCR(real time quantitative PCR,RT-qPCR)法检测143例肺癌组织及同源非癌变组织中Ubc9的表达情况,并对临床病理资料进行分析。结果:与癌旁组织相比,Ubc9在肺癌组织中呈高表达(P<0.05),Ubc9的表达与年龄、淋巴结转移、TNM分期及预后密切相关,有统计学意义(P<0.05);而与性别、病理学类型、组织分化程度无关。结论:小细胞肺癌、肺鳞癌和肺腺癌中均有Ubc9阳性表达,均高于正常的肺组织,并且与肺癌淋巴结转移程度相关,提示Ubc9可能与肺癌细胞的转移特性有关。
基金supported by grants from the National Natural Science Foundation of China (No. 30972785,30801376,30973505,30945201)Sun Yat-sen Excellent Medicine Youth Project,the Science and Technology Foundation of Guangdong Province (No.2009B030801005,2008B030301092)Foundation of Guangzhou Science and Technology Bureau (No.2009Y-C011-1)
文摘Ubiquitin-conjugating enzyme 9(Ubc9),the sole conjugating enzyme for sumoylation,regulates protein function and plays an important role in tumorigenesis.Whether Ubc9 is involved in the chemoresistance of breast cancer remains unknown.In this study,we aimed to evaluate the contribution of Ubc9 in the chemoresistance of breast cancer.Immunohistochemistry(IHC) was used to examine the expression level of Ubc9.Chi-square test,Wilcoxon test,and one-way ANOVA were applied to analyze the relationship between Ubc9 expression,clinicopathologic features,and clinical response to neoadjuvant chemotherapy.The significance of variables for survival was analyzed by the Cox proportional hazards model in a multivariate analysis.Kaplan-Meier survival curves were plotted and log-rank test was performed.The proportion of Ubc9-positive cells was higher in invasive ductal carcinoma than in normal breast tissues [(48.48 ± 17.94)% vs.(5.82 ± 2.80)%,P < 0.001].High Ubc9 expression was associated with poor differentiation(χ2 = 6.538,P = 0.038),larger tumor size(χ2 = 4.701,P = 0.030),advanced clinical stage(χ2 = 4.651,P = 0.031),lymph node metastasis(χ2 = 9.913,P = 0.010),basal-like phenotype(χ2 = 8.660,P = 0.034),and poor clinical response to neoadjuvant chemotherapy(χ2 = 11.09,P = 0.001).The expected 6-year cumulative disease-free survival rate was 87.32% in patients with low Ubc9 expression compared to 68.78% in those with high Ubc9 expression(χ2 = 4.289,P = 0.038).These data indicate that high Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis.
